Our Expertise

Personalized Medicine partnerships rely on technologies in which bioMérieux has a long history of established expertise: 

• Microbiology
• Immunoassays
• Molecular Biology
   

These mandatory diagnostic tests are used to select patients likely to show a clear benefit from an intervention (therapy, vaccine or device) for a given disease (patient stratification) and to identify patients with predispositions to serious side effects.

• bioMérieux has acquired significant experience in this field, working with major pharmaceutical companies such as GSK, Novartis, Pfizer to develop THXID^®-BRAF (a molecular-based Companion Diagnostic test to identify melanoma patients with BRAF V 600E/K mutations) as well as with other pharmaceutical partners to develop immunoassay-based CDx candidates. 

These diagnostic tests are recommended for safe drug or vaccine prescription or medical device use, and for good medical practice.

• Tests used to optimize clinical trials through patient stratification and cohort enrichment.
  • Many of the tests on the BIOFIRE^® (e.g. Respiratory panels) and VIDAS^® systems (NEPHROCHECK^® in the field of AKI), as well as certain microbiology growth-based assays (RAPIDEC^® CARBA NP, CHROMID^®), can be used to efficiently select patients for treatment with prophylactic or therapeutic monoclonal antibodies, anti-infective medications or immuno-modulatory drugs as well as drugs involved in AKI.

• Tests recommended for safe drug or vaccine utilization or effective medical device use, and for good medical practice.
  • In particular, tests used to determine antibiotic susceptibility (e.g. Minimum Inhibitory Concentration (MIC)) and to accompany their safe prescription.
  • For many years, bioMérieux has applied its partnership know-how in the field of infectious diseases to coordinate the development of the ETEST^® and VITEK^® 2 product ranges, in close collaboration with anti-infective pharmaceutical companies. Both these diagnostic solutions play an instrumental role in supporting the adoption and safe prescription of new anti-infective medications and avoiding their misuse, particularly in the context of growing antimicrobial resistance.